Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 01/09/2026 +03			5-day change	1st Jan Change
12.89 ^USD	-0.77%		-6.80%	+57.58%

08-28	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT
08-03	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

5af47.JDdHF8dvaCroK9SAAIP72YNVw8CFtexJNd6N8mOYhn0.XQQjI4tdOWTYQ5jEYsq2l_UCrKjR4dp-b7fHxRf_60hWaHBNpDYEGalChQ~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
01-07	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
11-14	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
06/05/25	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
31/10/24	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
31/10/24	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
06/09/24	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
13/08/24	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
27/03/24	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
21/03/24	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
12/03/24	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
01/03/24	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
26/02/24	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
13/12/23	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
12/12/23	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
26/10/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
24/10/23	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23/10/23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
22/09/23	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
16/08/23	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
15/08/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
10/05/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
05/04/23	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT
23/03/23	HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	MT
21/03/23	Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+59.1%
	WUXI APPTEC CO., LTD.					+18.83%
	ARGENX SE					+12.23%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.45%
	INSMED INCORPORATED					+64.33%
	BIONTECH SE					+18.32%
	PHARMAESSENTIA CORPORATION					-3.81%
	GENMAB A/S					+14.38%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.38%
	EXELIXIS, INC.					-1.74%
	Average					+22.25%
	Weighted average by Cap.					+19.10%